Who is sponsoring NCT01301833?

NCT01301833 is sponsored by Tanabe Pharma Corporation.

What condition does NCT01301833 study?

NCT01301833 studies Type 2 Diabetes Mellitus.

What drugs are being tested in NCT01301833?

Interventions: teneligliptin, glinide, biguanide, alpha-glucosidase inhibitor.

What is the status of NCT01301833?

NCT01301833 is currently COMPLETED.

Last reviewed 2025-12-15 · How we verify

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus

NCT01301833 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.

Details

Lead sponsor	Tanabe Pharma Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	462
Start date	2011-02
Completion	2012-09

Conditions

Type 2 Diabetes Mellitus

Interventions

teneligliptin
glinide
biguanide
alpha-glucosidase inhibitor

Primary outcomes

Number of Participants With Adverse Events — 52 Weeks
Treatment-emergent adverse events (TEAE) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after receiving the last dose of study drug.

Countries

Japan